Pulmonary hypertension (PH) is a chronic, life-threatening condition involving high blood pressure in the arteries of the ...

An incredible 18 million American men are battling erectile dysfunction, a condition that causes difficulty achieving and maintaining an erection, but can you get treatment for it ...

Wells Fargo raised the firm’s price target on Keros Therapeutics (KROS) to $28 from $11 and keeps an Overweight rating on the ...

Treating PAH patient-derived blood vessel cells with calcitriol reduced vitamin D receptor deficiency and suppressed their ...

A case series showed that chimeric antigen receptor T-cell therapy targeting CD19 halted the progression of fibrotic organ ...

Investors seemed to panic after the announcement, with a sell-off driving Keros' share price down 73%, reversing strong gains ...

Ralinepag (APD-811) is under development for the treatment of pulmonary arterial hypertension (PAH). It is a next-generation drug that is administered through oral route. It acts by targeting PGI2 ...

After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension ...

Keros Therapeutics said on Thursday that it has voluntarily halted usage of its 3.0 milligram (mg) and 4.5 mg doses of its ...

BofA lowered the firm’s price target on Keros Therapeutics (KROS) to $33 from $77 and keeps a Buy rating on the shares after the company ...

Keros Therapeutics, Inc.'s stock plummets 75% due to safety concerns in Phase 2 trial, but partnership with Takeda may offer ...

Keros Therapeutics Inc. shares lost over three-quarters of their market capitalization on Thursday, marking an all-time low, ...